Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the fifth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

Learn how a newly discovered virus disrupts its host’s nucleus in ways that echo how complex cells may have formed billions ...

Across the world, only a few dozen people appear to carry a genetic glitch that lets them brush off viruses that flatten ...